Hikma Pharmaceuticals (LON:HIK) Sets New 1-Year Low - What's Next?

Key Points

• Hikma Pharmaceuticals reached a new 12-month low, trading at GBX 1,686 ($22.74) before closing at GBX 1,695 ($22.87) with significant trading volume.
• Recent analyst ratings indicate a mixed outlook, with JPMorgan and Deutsche Bank lowering their price targets, while Jefferies maintained a "buy" rating and a target of GBX 2,600.
• Insider activity has been notable, with the purchase of 200,000 shares by Mazen Darwazah at GBX 1,756 per share, indicating confidence from company insiders.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price reached a new 52-week low on Monday . The stock traded as low as GBX 1,686 ($22.87) and last traded at GBX 1,695 ($22.99), with a volume of 326848 shares. The stock had previously closed at GBX 1,722 ($23.36).

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HIK shares. Jefferies Financial Group reissued a "buy" rating and issued a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. JPMorgan Chase & Co. cut their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of "Buy" and an average target price of GBX 2,627.50.

Hikma Pharmaceuticals Stock Performance

The stock has a market capitalization of £3.61 billion, a price-to-earnings ratio of 977.25, a P/E/G ratio of 2.38 and a beta of 0.41. The company's fifty day simple moving average is GBX 1,861.75 and its 200 day simple moving average is GBX 1,963.35. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Laura Balan Balan bought 3,500 shares of the stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 200,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The shares were purchased at an average cost of GBX 1,756 per share, with a total value of £3,512,000. Company insiders own 17.76% of the company's stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.